The upregulation of b‐FGF itself has been observed in tumours inherently resistance to anti‐VEGF therapy and notably those harbouring a local hypoxic environment (Casanovas et al., 2005; Yoshiji et al., 1997). The gene discussed is FGF2; the disease is neoplasm.